|
| Status |
Public on Oct 06, 2015 |
| Title |
sample_159_03-AA-004 [expression] |
| Sample type |
RNA |
| |
|
| Source name |
Breast cancer, CHER-LOB Arm B, pre-treated
|
| Organism |
Homo sapiens |
| Characteristics |
disease state: HER2-positive breast cancer
tissue: breast cancer
cher-lob arm: B
arm description: chemotherapy+lapatinib
pcr (1=yes): 0
|
| Treatment protocol |
CHER-LOB is a phase II, randomized, multicenter, trial in which 121 patients with primary HER2-positive breast cancer were randomized to receive preoperative chemotherapy with weekly paclitaxel times 12 followed by 4 courses of 3-weekly FEC (fluorouracil, epirubicin and cyclophosphamide) plus either trastuzumab (Arm A), lapatinib (Arm B) or the combination of trastuzumab and lapatinib (Arm C). The trial design, eligibility criteria, statistical analysis, and clinical results including response, surgery outcomes and treatment safety are described in details elsewhere.
|
| Growth protocol |
NA
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Qiagen RNeasy (manufacturer's protocol).
|
| Label |
Biotin
|
| Label protocol |
Affymetrix GeneChip® 3' IVT Express Kit (manufacturer's protocol).
|
| |
|
| Hybridization protocol |
Affymetrix Human Genome U133 Plus 2.0 array (manufacturer's protocol).
|
| Scan protocol |
Affymetrix GeneChip Scanner 3000 7G (manufacturer's protocol).
|
| Data processing |
Partek GS.
|
| |
|
| Submission date |
Feb 25, 2015 |
| Last update date |
Jun 06, 2022 |
| Contact name |
Enrico Tagliafico |
| E-mail(s) |
enrico.tagliafico@unimore.it
|
| Organization name |
University of Modena and Reggio Emilia
|
| Department |
Center for Genome Research
|
| Street address |
Via Campi 287
|
| City |
Modena |
| State/province |
MO |
| ZIP/Postal code |
41126 |
| Country |
Italy |
| |
|
| Platform ID |
GPL570 |
| Series (2) |
| GSE66305 |
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with chemotherapy plus trastuzumab and lapatinib as neoadjuvant therapy for HER2-positive breast cancer [expression] |
| GSE66399 |
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with chemotherapy plus trastuzumab and lapatinib as neoadjuvant therapy for HER2-positive breast cancer |
|
| Relations |
| Reanalyzed by |
GSE205568 |
